Definium Therapeutics/$DFTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Definium Therapeutics
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Ticker
$DFTX
Sector
Primary listing
Employees
106
Headquarters
Website
DFTX Metrics
BasicAdvanced
$2.7bn
-
-$2.49
2.38
-
Price and volume
Market cap
$2.7bn
Beta
2.38
52-week high
$26.25
52-week low
$6.35
Average daily volume
2m
Financial strength
Current ratio
4.692
Quick ratio
4.604
Long term debt to equity
14.622
Total debt to equity
14.622
Interest coverage (TTM)
-31.57%
Profitability
Management effectiveness
Return on assets (TTM)
-35.72%
Return on equity (TTM)
-94.70%
Valuation
Price to book
9.13
Price to tangible book (TTM)
9.84
Price to free cash flow (TTM)
-16.108
Free cash flow yield (TTM)
-6.21%
Free cash flow per share (TTM)
-1.52
Growth
Earnings per share change (TTM)
135.49%
3-year earnings per share growth (CAGR)
9.59%
What the Analysts think about DFTX
Analyst ratings (Buy, Hold, Sell) for Definium Therapeutics stock.
DFTX Financial Performance
Revenues and expenses
DFTX Earnings Performance
Company profitability
DFTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs